A brazilian nationwide multicenter study on deficiency of deaminase-2 (DADA2)

Adv Rheumatol. 2023 May 22;63(1):23. doi: 10.1186/s42358-023-00303-5.


Introduction: The deficiency of ADA2 (DADA2) is a rare autoinflammatory disease provoked by mutations in the ADA2 gene inherited in a recessive fashion. Up to this moment there is no consensus for the treatment of DADA2 and anti-TNF is the therapy of choice for chronic management whereas bone marrow transplantation is considered for refractory or severe phenotypes. Data from Brazil is scarce and this multicentric study reports 18 patients with DADA2 from Brazil.

Patients and methods: This is a multicentric study proposed by the Center for Rare and Immunological Disorders of the Hospital 9 de Julho - DASA, São Paulo - Brazil. Patients of any age with a confirmed diagnosis of DADA2 were eligible for this project and data on clinical, laboratory, genetics and treatment were collected.

Results: Eighteen patients from 10 different centers are reported here. All patients had disease onset at the pediatric age (median of 5 years) and most of them from the state of São Paulo. Vasculopathy with recurrent stroke was the most common phenotype but atypical phenotypes compatible with ALPS-like and Common Variable Immunodeficiency (CVID) was also found. All patients carried pathogenic mutations in the ADA2 gene. Acute management of vasculitis was not satisfactory with steroids in many patients and all those who used anti-TNF had favorable responses.

Conclusion: The low number of patients diagnosed with DADA2 in Brazil reinforces the need for disease awareness for this condition. Moreover, the absence of guidelines for diagnosis and management is also necessary (t).

Keywords: Autoinflammatory diseases; Deficiency of adenosine deaminase 2; Immune dysregulation; ada2.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Deaminase* / genetics
  • Brazil
  • Humans
  • Intercellular Signaling Peptides and Proteins / genetics
  • Tumor Necrosis Factor Inhibitors
  • Vasculitis*


  • Adenosine Deaminase
  • Tumor Necrosis Factor Inhibitors
  • Intercellular Signaling Peptides and Proteins